NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
Clinical Trials
11 trialsNCT05386888 2025-10-02
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Completed
NCT04991506 2025-06-23
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Completed
NCT05102006 2025-06-03
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT04914286 2025-05-14
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Completed
NCT05830539 2025-05-02
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Completed
NCT05188664 2025-02-17
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Completed
NCT05031494 2025-01-06
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Completed
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT04357756 2023-09-13
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed